Elastomeric Infusion System Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Syringe Infusion Pumps, Volumetric Infusion Pumps, Elastomeric Infusion Pumps, Insulin Infusion Pumps, Enteral Infusion Pumps, and Other Product Types), By Mechanism of Action (Continuous Infusion and Intermittent Infusion), By Application (Oncology, Anaesthesia, Pain Management, Chemotherapy, and Paediatric Care), By End User (Hospitals, Home Care Settings, Ambulatory Surgical Centers, and Nursing Homes) and Region Forecast 2020-2031

Elastomeric Infusion System Market size was valued at US$ 665.8 million in 2024 and is expected to reach US$ 1,119.1 million by 2031, growing at a significant CAGR of 7.7% from 2025-2031. Moreover, the U.S. Elastomeric Infusion Systems Market is projected to grow significantly, reaching an estimated value of US$ 349.1 Million by 2031. The market represents a vital component of modern healthcare, providing a means for controlled and precise administration of medications to patients across various clinical settings. The market is primarily driven by the global shift toward home-based and ambulatory care, offering a cost-effective, comfortable alternative to prolonged hospital stays.

These pumps enable continuous, controlled drug delivery, ideal for antibiotics, chemotherapy, and pain management, without relying on electricity or complex programming. Rising chronic disease burdens, increased surgical volume, and growing elderly populations further fuel demand. A major trend is the integration of smart technologies, including digital sensors and wireless connectivity, enabling real-time monitoring and remote dose adjustments. This digital transformation supports the global push for decentralized healthcare and better treatment adherence.

A key opportunity lies in the expanding role of home infusion therapies, especially in emerging markets and post-operative care, backed by favorable reimbursement models and technological innovation. However, the market faces a notable restraint in the form of flow rate variability, as elastomeric pumps are less precise than electronic alternatives. Challenges also include limited awareness, reimbursement gaps, and lack of dosage flexibility, which can hinder widespread adoption in critical care settings.

Facts & Figures

• Rise in Home-Based & Ambulatory Care: Healthcare systems are increasingly shifting care from hospitals to home settings to reduce costs and improve patient comfort. Elastomeric pumps, being portable, disposable, and electricity-free, are ideal for self-administered drug delivery. For instance, India’s PM-JAY scheme reimbursed over 95,000 elastomeric antibiotic courses in 2023, nearly doubling year-over-year, showing rapid home-care adoption.
• Increasing Burden of Chronic Illnesses: Chronic diseases like cancer, diabetes, and post-surgical infections require prolonged infusion therapies. Elastomeric systems offer continuous, reliable drug delivery with minimal supervision. In 2024, the WHO projects a significant increase in global cancer cases, with an estimated 20 million new cases and 9.7 million deaths in 2022. By 2050, the cancer burden is expected to grow by 77%.
• Technological Innovations: Advancements in elastomeric pump design, like controlled flow restrictors, tamper-proof valves, and improved biocompatible materials, enhance safety and usability. For instance, in June 2025, OncoDesign Paris and Qualcomm developed NB-IoT–enabled elastomeric pumps for real-time infusion monitoring—a major leap in smart drug delivery.
• Favorable Government and Reimbursement Policies: Elastomeric pumps help minimize hospital-acquired infections by reducing inpatient time. This aligns with global efforts to curb nosocomial risks, especially in immunocompromised patients. Hospitals in Europe and Asia have adopted elastomeric pumps in post-op protocols to cut infection rates and costs, noted in NHS UK’s 2024 infection control roadmap.

Key Developments:

• In June 2025, OncoDesign Paris partnered with Qualcomm to embed ultra-low-power NB?IoT chips into its disposables, enabling real-time “residual volume” reporting every 30?minutes—paving the way for smart elastomeric pumps with remote adherence dashboards.
• In May 2025, ICU Medical and Otsuka Pharmaceutical Factory completed their joint venture to create a North American IV solutions manufacturing network (1.4?billion units/year), adding resiliency and innovation, including elastomeric infusion sets, to the region’s supply chain.
• In April 2025, ICU Medical received FDA 510(k) clearance for its single? and dual-channel Plum Solo and Duo infusion pumps, laying the groundwork for integrated elastomeric?electronic hybrid systems in home and hospital settings

Elastomeric Infusion Systems Market Segmentation:

Based on the product type:

• Syringe Infusion Pumps
• Volumetric Infusion Pumps
• Elastomeric Infusion Pumps
• Insulin Infusion Pumps
• Enteral Infusion Pumps
• Other Product Types

Among the various product types, volumetric infusion pumps hold the largest market share in the global infusion systems market. Their precise and continuous fluid delivery capabilities make them indispensable in critical care settings such as ICUs, neonatal care, and emergency departments. These pumps offer accuracy in administering large volumes of fluids, medications, or nutrients, making them the preferred choice in hospital environments. Their ability to handle multiple infusions and compatibility with a wide range of solutions further enhances their utility. On the other hand, Enteral Infusion Pumps, though vital for nutritional therapy, represent the smallest market share due to their niche usage and limited demand in acute care settings.

Based on the mechanism of action:

• Continuous Infusion
• Intermittent Infusion

Continuous infusion holds the largest market share in the infusion systems market due to its wide application in delivering a steady and controlled dose of medications such as antibiotics, analgesics, chemotherapy agents, and insulin over extended periods. This mechanism is especially preferred in critical care, oncology, and post-operative recovery, where maintaining constant plasma drug levels is essential for therapeutic efficacy. Its convenience in reducing frequent dosing and minimizing fluctuations in drug concentration further supports its dominance. In contrast, intermittent infusion, used for scheduled, periodic drug administration, occupies a smaller share, primarily limited to specific treatments like hydration therapy or time-bound antibiotic delivery.

Based on the application:

• Oncology
• Anaesthesia
• Pain Management
• Chemotherapy
• Paediatric Care

Among the application segments, oncology holds the largest market share in the market. This dominance is due to the rising global burden of cancer and the growing need for continuous, controlled chemotherapy infusions that can be administered in outpatient or home care settings. Elastomeric pumps are especially favoured in oncology for their portability, ease of use, and reduced need for hospital stays. Their use improves patient comfort and adherence during long-term treatments. Additionally, the growing emphasis on ambulatory cancer care further boosts this segment. On the other hand, Paediatric care accounts for the smallest share, primarily due to limited adoption and dosage precision concerns in infants and children.

Based on the end user:

• Hospitals
• Home Care Settings
• Ambulatory Surgical Centers
• Nursing Homes

Among the end users, hospitals hold the largest market share in the market. This is primarily driven by the high volume of surgical procedures, cancer treatments, and inpatient care requiring controlled and continuous drug delivery. Hospitals are better equipped with trained personnel to handle infusion-related complications, making them the preferred setting for complex treatments like chemotherapy, analgesia, and post-operative care. Additionally, institutional procurement and favorable reimbursement support the dominance of this segment. However, with the growing demand for cost-effective and comfortable care, Home Care Settings are rapidly gaining traction. Meanwhile, Nursing Homes currently represent the smallest market share, due to limited adoption of infusion technologies and budgetary constraints.